Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
D. C. Cho
Institutions:
City Of Hope National Medical Center,
Beth Israel Deaconess Medical Center,
Massachusetts General Hospital,
Dana-Farber Cancer Institute,
Vanderbilt-Ingram Cancer Center,
University of Pennsylvania
show all 6
Observed institutions:
City Of Hope National Medical Center,
Beth Israel Deaconess Medical Center,
Mayo Clinic,
Massachusetts General Hospital,
Dana-Farber Cancer Institute,
Vanderbilt-Ingram Cancer Center,
University of Pennsylvania
show all 7
OpenAlex ID:
A5042384361
Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
2010
·
D. Michaelson
, D. F. McDermott
, et al.
·
Journal of Clinical Oncology
·
12
A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI)
2009
·
D. C. Cho
, R. A. Figlin
, et al.
·
Journal of Clinical Oncology
·
12
Pneumonitis associated with mTOR therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings, and correlation with clinical outcome.
2011
·
D. A. Dabydeen
, J. P. Jagannathan
, et al.
·
Journal of Clinical Oncology
·
5
A phase II pilot trial of low dose, continuous infusion, or “metronomic”, paclitaxel and oral celecoxib in patients with metastatic melanoma
2006
·
D. F. McDermott
, D. C. Cho
, et al.
·
Journal of Clinical Oncology
·
3
Patient-reported side effects from molecularly targeted therapies in renal cell carcinoma (RCC).
2010
·
V. J. Seery
, B. M. McGree
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
5
Citation count:
32
H-index:
3
I10-index:
2
Year
Topic
Type